CMD-502 is an off-the-shelf allogeneic product which is under development for the treatment of hematological cancers (target undisclosed). CMD-502 will be manufactured in large amounts to enable the treatment of patients on an immediate basis.

CMD-502 takes advantage of the unique characteristics of NKT cells for an off-the-shelf product.  The T cell receptor of NKT cells is invariant and does not target human antigens.  Allogeneic CAR-modified NKT cells can be administered to patients with minimal risk of toxicity due to Graft vs Host Disease. 1